通心络联合瑞舒伐他汀治疗冠心病合并转氨酶升高的疗效观察

目的：探讨通心络胶囊联合瑞舒伐他汀对冠心病合并转氨酶升高患者的治疗疗效。方法：连续入选60例冠心病患者，谷丙转氨酶（ALT）均大于120u/L；随机分两组，各30例，治疗组加用瑞舒伐他汀5mg/次，1次/晚，通心络胶囊（河北以岭药业生产），3粒/次，3次/d，持续6个月的治疗；进行10个月临床随访，记录心脑血管事件的发生情况。结果：10个月后随访时，治疗组的血脂及 hs-CRP 等血液指标，急性心脑血管意外发生率均显著低于对照组；与对照组比较差别有统计学意义，而转氨酶的变化两组之间差异，无统计学意义。结论：转氨酶升高的冠心病患者加用通心络胶囊联合他汀类药物治疗，能有效降低血脂及hs-CRP，降低心脑血管意外及再住院率，效果肯定。

Clinical observation on treating coronary heart disease with high level of transaminases with Tongxinluo capsule and Rosuvastatin

To observe the effect of Rosuvastatin and Tongxinluo capsule on treating coronary heart disease with high level of tmnsaminases. Methods： 60 patients with CHD that were continuously enrolled in this study, whose Alanine aminotransferase （ALT） were more than 120u/L. 60 patients were randomly divided into two groups, with 30 patients in each group. The treated group was given the Rosuvastatin, 5mg/firne, 1 time/d, Tongxirduo capsule 3 pills every time, 3 times/d, continuing treating for at least 6 months. Observe the treatment effect. follow-upl0 months. Results： The treated group patients＇ blood fat, hs-CRP and other blood index_s were much better than control group, the acute cerebrovascular accidents is lower too; statistically significant （P〈0.05）. The transaminase change between the two groups had no differences. Conclusion： Rosuvastatin and Tongxinluo capsule can effectively reduce blood fat and hs-CRP on admission to reduce heart cerebrovascular accident and hospital admission rates .It has the function in treating coronary heart disease with high level oftransaminases.